Nuvation Bio Inc. (NUVB) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.58: Risk below floor (2.5 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 8.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Elevated put/call ratio: 10.00; Below-average business quality.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It... Read more
Sell if holding. Engine safety override at $4.58: Risk below floor (2.5 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 8.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Elevated put/call ratio: 10.00; Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Score 4.9/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-10Recent Developments — Nuvation Bio Inc.
Latest news
- NEWS Nuvation Bio To Showcase New Outcomes Data From Its Pivotal TRUST-II Trial Of IBTROZI In Participants With Advanced ROS1 — benzinga May 27, 2026 positive
- NEWS Nuvation Bio Collaborates With Thermo Fisher Scientific For U.S.-Based Manufacturing Of IBTROZI — benzinga May 13, 2026 positive
- NEWS RBC Capital Reiterates Outperform on Nuvation Bio, Maintains $20 Price Target — benzinga May 5, 2026 positive
- NEWS Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target — benzinga May 5, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $17 Price Target — benzinga May 5, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Volatile — 8.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.58: Risk below floor (2.5 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 8.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Elevated put/call ratio: 10.00; Below-average business quality. Chart setup: RSI 52 mid-range, Bollinger mid-band. Prior stop was $4.26. Score 4.9/10, moderate confidence.
Take-profit target: $10.73 (+134.3% upside). Prior stop was $4.26. Stop-loss: $4.26.
Risk below floor (2.5 < 3.0).
Nuvation Bio Inc. trades at a P/E of N/A (forward -82.2). TrendMatrix value score: 6.2/10. Verdict: Sell.
17 analysts cover NUVB with a consensus score of 4.1/5. Average price target: $12.
What does Nuvation Bio Inc. do?Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer...
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.